Deerfield, IL - The selective A2A adenosine-receptor agonist regadenoson (Lexiscan) is now commercially available for performing resting stress-myocardial perfusion scans, announced Astellas Pharma US, which is marketing the product for its developer and owner, CV Therapeutics . Lexiscan had been approved by the FDA in April of this year .
As reported by heart wire at the time, the pharmacologic stressor's approval was based on two phase 3 studies in which its perfusion scans were comparable in quality to those made using another Astellas product, adenosine injection (Adenoscan). Astellas Pharma US is an affiliate of Astellas Pharma Inc of Tokyo.
Unlike Adenoscan, Lexiscan is administered as a non-weight-adjusted rapid IV bolus; Astellas says that its adenosine-receptor selectivity should give the agent a better side-effect profile.
Heartwire from Medscape © 2008
Cite this: Selective adenosine-receptor agonist for resting perfusion scans now on the market - Medscape - Jun 24, 2008.